ARA-290 is a variant of erythropoietin which has been shown to decrease inflammatory pathways through paracrine signaling and the innate repair receptors. Research has shown ARA-290 to help reduce HbA1c, improve cholesterol, modulate peripheral neuropathies and general neuropathic pain and stimulates wound repair

THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

What is ARA-290?

ARA-290 is a small peptide derived from the helix beta domain of erythropoietin (EPO). EPO has long been known to exhibit actions beyond the stimulation of red blood cell production in bone marrow. The glycoprotein, which is made in the kidney, has been found to stimulate blood vessel growth, promote cell survival, alter blood pressure, and produce neuroprotective effects in diabetic neuropathy. ARA-290 offers the neuroprotective and pain relieving effects of EPO without stimulating red blood ell production[1]. ARA-290 has completed phase II trials and is in preparation to enter phase III trials for a variety of applications in diabetes and the autoimmune sarcoidosis. Right now, the peptide is of active interest for its ability to control neuropathic pain, but it is also under investigation as a potential stimulator of wound repair in chronic diabetes, as an immune modulatory drug, and as a potential treatment for systemic lupus erythematosus (lupus or SLE).

ARA-290 Structure

Sequence: ZEQLERALNSS Molecular Formula: C51H84N16O21 Molecular Weight: 1257.3 g/mol PubChem CID: 91810664 CAS No: 1208243-50-8 Synonyms: cibinetide, PH-BSP

ARA-290 Research

Blood Vessel Health

Retinal ischemia, which results from a number of disease processes, is a leading cause of blindness in industrialized nations. The ability to protect retinal epithelial cells from injury or the ability to promote their regeneration following an insult, could go a long way to reducing disease burden. Research in mice indicates that ARA-290 can protect endothelial colony forming cells against the ravages of inflammation. In so doing, ARA-290 prolongs cell survival and helps endothelial colony forming cells (ECFCs) to repair and rebuild blood vessels[2].

Other studies in mice show that ARA-290 enhances the proliferation, migration, and longevity of ECFCs throughout the vasculature. It also appears that ARA-290 boosts the homing ability of ECFCs, helping them to better target areas of the vasculature that are in need of repair. There is hope that this function can not only help to boost the effects of endogenous ECFCs, but can help to improve the ability of transplanted ECFCs to repair vasculature and restore blood flow to ischemic tissue[3]. If successful in the case of ECFC transplants, ARA-290 could open up a whole new area of medical therapy allowing functional cells to be transplanted successfully for tissue repair, hormone production, protein building, and more.

Reducing Inflammatory Cytokines 

Research in mice shows that ARA-290 can hep to promote the survival of transplanted islet cells by inhibiting macrophage activation. For years, the treatment of diabetes via the transplantation of healthy insulin-producing islet cells has been the holy grail of endocrinology. Islet cells, unlike exogenous insulin, provide a much more physiologic control of blood sugar and therefore drastically reduce the complications often seen even in well-controlled diabetes. Unfortunately, islet cells do not survive transplantation for long and thus the procedure has been all but abandoned. With the development of ARA-290, however, that may be changing. Studies in mice have revealed that the peptides ability to suppress inflammatory cytokines like IL-6, IL-12, and TNF-alpha drastically prolongs the survival of transplanted islet cells[4].

The ability of ARA-290 to protect against normal inflammatory responses appears to be mediated through the binding of the peptide to the tissue-protective receptor (TPR), boosting tissue protection and helping to regulate the immune system. EPO also binds to the TPR, but has a number of cardiovascular and hematopoietic side effects that have made it untenable as a treatment in many if not most settings. By binding to the TPR and not promoting some of the other effects of EPO, peptides like ARA-290 help to reduce apoptosis and cut back on the levels of harmful inflammatory cytokines. The net results are tissue protection and improved tissue regeneration. Both of these features lead to reduced morbidity and mortality, fast wound healing, reduced scar formation, and fast post-injury recovery of function[5].

Tissue Protection

Research in mice shows that ARA-290 can help to promote the survival of transplanted islet cells by inhibiting macrophage activation. For years, the treatment of diabetes via the transplantation of healthy insulin-producing islet cells has been the holy grail of endocrinology. Islet cells, unlike exogenous insulin, provide a much more physiologic control of blood sugar and therefore drastically reduce the complications often seen even in well-controlled diabetes. Unfortunately, islet cells do not survive transplantation for long and thus the procedure has been all but abandoned. With the development of ARA-290, however, that may be changing. Studies in mice have revealed that the peptides ability to suppress inflammatory cytokines like IL-6, IL-12, and TNF-alpha drastically prolongs the survival of transplanted islet cells[4].

The ability of ARA-290 to protect against normal inflammatory responses appears to be mediated through the binding of the peptide to the tissue-protective receptor (TPR), boosting tissue protection and helping to regulate the immune system. EPO also binds to the TPR, but has a number of cardiovascular and hematopoietic side effects that have made it untenable as a treatment in many if not most settings. By binding to the TPR and not promoting some of the other effects of EPO, peptides like ARA-290 help to reduce apoptosis and cut back on the levels of harmful inflammatory cytokines. The net results are tissue protection and improved tissue regeneration. Both of these features lead to reduced morbidity and mortality, fast wound healing, reduced scar formation, and fast post-injury recovery of function[5].

Immune System

The TPR is expressed on a variety of immune cells including macrophages, dendritic cells, mast cells, and lymphocytes (particularly T-cells). Mounting evidence suggests that ARA-290 and similar peptides can bind to this TPR on immune cells to directly affect their function.

For macrophages, stimulation of the TPR by ARA-290 significantly reduces the excretion of proinflammatory cytokines like TNF-alpha and IL-6. Interestingly, even though this downregulation of the immune response leads to decreased pathogen clearance in certain settings, it reduces disease severity and helps to prevent long-term disease processes from setting up. Research also shows that activation of TPR restricts the pathway of macrophage chemokine secretion, which in turn lessens the infiltration of inflammatory cytokines while boosting the recruitment tissue macrophages (resident macrophages) to areas of injury. The net result appears to be improved tissue healing with reduced inflammatory side effects.

Other research shows that ARA-290 may help to alter antigen presentation by dendritic cells, thereby altering the adaptive immunity that leads to long-term resistance against pathogens to which the body has already been exposed. While this sounds like a very bad thing on its surface, it is important to remember that adaptive immunity is the primary driver of organ and tissue rejection following transplant. The ability to modulate the process and fine tune it can help to reduce graft rejection in everything from kidney and heart transplants to bone marrow transplants and experimental transplants[5], [6].

There are several applications for an immune system modulator like ARA-290. Perhaps the most promising is in the setting of colitis. Colitis, which can be a consequence of infection, can also be a result of chronic automimmune disease such as is seen in Crohn’s disease and ulcerative colitis. Currently the treatments for autoimmune colitis are limited to injectable medications with a myriad of side effects. The ability to treat colitis with more selective immune modulators could ease the suffering of many people who suffer from inflammatory bowel disease[7].

Another potential avenue of the immune modulatory effects of ARA-290 is in the treatment of systemic lupus erythematosus (SLE). Research in mice shows that administration of ARA-290 suppresses levels of autoantibodies (namely ANA and anti-dsDNA) that serve as markers for SLE diagnosis and as indicators of disease severity. Moreover, ARA-290 decreases the kidney damage that often leads to morbidity and mortality in SLE. These findings suggest that ARA-290 may offer the first truly targeted treatment for SLE[8].

Pain Perception

The immune system has long been known to play a role in the perception of pain (nociception), but effect regulators of this mechanism of pain have been hard to develop. In particular, the immune system plays an important role in the development of neuropathic (nerve-based) pain, such as the neuropathy seen in diabetes. Neuropathic pain is notoriously difficult to control, but research shows that targeting the IRR (innate repair receptor) can decrease inflammation and alleviate neuropathic pain. ARA-290 is known to act on this receptor, but new research suggests that it can also inhibit TRPV1 channel activity.[9]. The TRPV1 channel, also known as the capsaicin receptor, is responsible for the perception of heat and associated burning pain so often reported in neuropathic disease. The ability of ARA-290 to act on this receptor could make it useful in treating pain associated with diabetes, multiple sclerosis, chemotherapy, and amputation.

Small nerve fiber loss is a consequence of certain autoimmune diseases, particularly sarcoidosis and diabetes. Also called small fiber neuropathy, the condition results when small fibers in the skin that are responsible for temperature and pain sensation deteriorate. Symptoms, which range in severity, can be of the pins and needles type or give the sensation of sand in the shoe or a wrinkle in a sock. The pain is usually transient, but is severe and occurs multiple times throughout a day. In the worst cases, the pain becomes persistent and generally manifests as a burning sensation. Research in people suffering from small fiber nerve loss shows that treatment with ARA-290 increases the number of small nerve fibers and reduces pain significantly. This suggests that ARA-290 may offer an effective treatment for nerve damage seen in diseases like sarcoidosis, diabetes, thyroid dysfunction, celiac disease, HIV, and more[10], [11].

Orphan Drug

In 2016, Araim Pharmaceuticals announced that the FDA had granted it orphan drug status to explore the efficacy of daily cibinetide in the treatment of patients with painful sarcoid neuropathy. A year later, Chief Science Officer Michael Brines, along with several others, published a paper revealing the benefits of ARA-290 in the treatment of peripheral nerve pain and small nerve fiber pain.

According to Dr. Brines and his colleagues, ARA-290 (cibinetide) is preparing for phase 3 trials as a treatment for neuropathy. This peptide has the potential to treat the roughly 87 million Americans who suffer from nerve damage and its associated morbidities. There even appears to be a role for ARA-290 in accelerating impaired wound healing in mice with diabetes, suggesting that the peptide may help to stave off the amputations and chronic ulcers that many diabetics suffer later in life[12].

Summary

While ARA-290 has been of primary interest for its novel mechanism of controlling neuropathic pain, the peptide is also of interest for its immune modulating properties, for its ability to stimulate wound repair, and as a potential means of protecting vasculature during ischemic insults. The most advanced area of research surrounds the ability of ARA-290 to modulate neuropathic pain. The peptide is currently in phase II and III trials for the treatment of diabetic neuropathy and sarcoid neuropathy respectively. There is also interest in using the peptide as a treatment for systemic lupus erythematosus and in the pain syndromes associated with multiple sclerosis, HIV, celiac disease, and more. There is burgeoning interest in using ARA-290 as a potential disease modifying agent in inflammatory bowel disease as well.

ARA-290 exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. ARA-290 for sale at   peptide Review hub is limited to educational and scientific research only, not for human consumption. Only buy ARA-290 if you are a licensed researcher.

Scientific Journal Author

Dr. Michael Brines received a BS with highest honors in physics and biology from the University of Notre Dame and a PhD in neurobiology and behavior from The Rockefeller University. Subsequently, he earned his MD from Yale University and completed a residency in Internal Medicine at Yale-New Haven Hospital. Following residency, he completed fellowship training in Clinical Investigation, as well as Endocrinology, Diabetes, and Metabolism at Yale. Michael Brines is board certified in Internal Medicine as well as in Endocrinology, Diabetes, & Metabolism. Michael Brines has been the inventor or co-inventor on numerous US patents and foreign counterparts, and has authored or coauthored more than 100 scientific publications.

Michael Brines, M.D. is being referenced as one of the leading scientists involved in the research and development of ARA-290. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between   peptide Review hub and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Michael Brines is listed in [9] under the referenced citations.

ARA-290 (also known as Cibinetide and PH-BSP) is a synthetic peptide derived from the tissue-protective region of erythropoietin (EPO). Unlike EPO, ARA-290 has been specifically engineered to target tissue-protective and anti-inflammatory pathways without stimulating red blood cell production. Because of its unique biological profile, ARA-290 has attracted significant research interest in neuropathy, inflammation, immune modulation, vascular repair, wound healing, and tissue-protection studies.

As ARA-290 research continues to expand, researchers frequently compare suppliers based on purity, analytical testing, vendor transparency, customer reviews, and overall value.

This ARA-290 Vendor Price Comparison Guide helps researchers evaluate suppliers using objective criteria, including:

• Product Pricing

• Cost Per Milligram

• Peptide Purity

• Third-Party Testing

• Certificate of Analysis (COA)

• Vendor Reputation

• Customer Reviews

• Shipping Performance

• Product Availability

• Overall Value

Whether you're searching for the lowest-priced ARA-290 supplier, vendors with comprehensive laboratory testing, or peptide companies with the best reputation for quality, this guide provides a framework for comparison.

Explore ARA-290 Vendors by Criteria

Most Popular ARA-290 Vendors

Compare suppliers frequently selected by neuropathy, inflammation, and regenerative biology researchers.

Highest Reviewed ARA-290 Vendors

Discover vendors with strong customer satisfaction and positive marketplace feedback.

Lowest Price ARA-290 Vendors

Identify suppliers offering competitive pricing and attractive cost-per-milligram value.

Highest Purity ARA-290 Vendors

Review suppliers providing transparent purity verification and batch-specific testing.

Best Value ARA-290 Vendors

Compare quality standards, testing documentation, customer support, and pricing.

Fastest Shipping ARA-290 Vendors

Evaluate fulfillment speed, packaging quality, and delivery reliability.

Newly Listed ARA-290 Vendors

Explore recently launched suppliers offering ARA-290 research peptides.

What Is ARA-290?

Overview

ARA-290 is a small peptide derived from the helix-beta region of erythropoietin (EPO).

Researchers became interested in ARA-290 after discovering that certain beneficial effects of EPO were mediated through tissue-protective signaling pathways that are separate from red blood cell production.

Research involving ARA-290 has examined:

• Neuropathic pain

• Tissue repair

• Immune regulation

• Inflammatory signaling

• Vascular repair

• Wound healing

• Endothelial-cell biology

• Autoimmune disease pathways

Unlike EPO, ARA-290 does not appear to stimulate erythropoiesis, making it an attractive research tool for studying tissue-protective signaling.

Molecular Characteristics

Peptide Information

Researchers evaluating ARA-290 products should carefully review molecular specifications and analytical documentation.

Peptide Name

ARA-290

Alternative Names

• Cibinetide

• PH-BSP

Amino Acid Sequence

ZEQLERALNSS

Molecular Formula

C51H84N16O21

Molecular Weight

1257.3 g/mol

PubChem CID

91810664

CAS Number

1208243-50-8

Classification

Tissue-Protective Erythropoietin-Derived Peptide

Research Category

Neuropathy, Inflammation & Tissue Repair Research

Why Researchers Compare ARA-290 Vendors

Research quality depends heavily on peptide quality and analytical verification.

Differences among suppliers may include:

• Peptide purity

• Batch consistency

• Manufacturing standards

• Peptide stability

• Testing procedures

• Storage conditions

• Product documentation

• Customer support

Choosing a vendor based only on price may overlook important quality considerations.

How We Compare ARA-290 Vendors

Third-Party Laboratory Testing

Independent laboratory testing remains one of the strongest indicators of product quality.

Researchers should prioritize vendors providing:

• Third-party testing

• Identity verification

• Purity analysis

• Batch-specific reports

Certificate of Analysis (COA)

A high-quality COA should include:

• Testing date

• Batch number

• Purity results

• Identity verification

• Analytical methodology

Product Purity

Purity remains one of the most important factors when evaluating research peptides.

Suppliers that provide transparent purity reporting generally rank higher in quality assessments.

Cost Per Milligram

Comparing only vial pricing can create misleading conclusions.

Cost Per Milligram Formula

Product Price ÷ Total Milligrams = Cost Per Milligram

This allows meaningful comparisons across suppliers.

Customer Reviews

Customer experiences often provide insight regarding:

• Product consistency

• Packaging quality

• Shipping reliability

• Customer support

• Purchasing experience

Vendor Reputation

Established peptide suppliers frequently demonstrate:

• Consistent quality standards

• Reliable testing programs

• Strong customer satisfaction

• Long-term marketplace presence

Current Research & Evidence

Neuropathy Research

ARA-290 is best known for research involving neuropathic pain and small-fiber neuropathy.

Researchers have investigated its potential role in:

• Nerve repair pathways

• Neuropathic pain regulation

• Peripheral nerve health

• Small-fiber regeneration

This remains one of the most active areas of ARA-290 research.

Tissue-Protective Signaling Research

ARA-290 binds to tissue-protective receptors involved in cellular survival and regenerative signaling.

Researchers continue exploring how these pathways influence:

• Cellular recovery

• Tissue resilience

• Injury response

• Regenerative biology

Inflammation Research

Studies suggest ARA-290 may influence inflammatory pathways by modulating cytokine activity.

Research has examined interactions involving:

• TNF-alpha

• IL-6

• IL-12

• Macrophage signaling

• Immune regulation

These mechanisms remain under active investigation.

Wound-Healing Research

Researchers continue studying ARA-290's relationship with:

• Tissue regeneration

• Wound repair pathways

• Scar formation

• Cellular healing responses

Interest has been particularly strong in diabetic wound-healing research.

Key Findings on ARA-290 Research

Blood Vessel Health Research

Experimental studies suggest ARA-290 may support pathways involved in vascular repair and endothelial-cell function.

Researchers continue investigating:

• Vascular regeneration

• Endothelial cell biology

• Blood-vessel maintenance

• Ischemic tissue repair

Immune-System Research

Activation of tissue-protective receptors may influence immune-cell behavior.

Research involving ARA-290 has examined:

• Macrophage activity

• Dendritic-cell signaling

• Cytokine production

• Inflammatory balance

This has generated interest in autoimmune and inflammatory disease research.

Neuropathic Pain Research

One of the most advanced areas of ARA-290 investigation involves neuropathic pain signaling.

Researchers continue studying potential interactions with:

• Pain pathways

• Sensory nerve function

• Inflammatory pain signaling

• Neurological recovery mechanisms

Autoimmune Disease Research

ARA-290 has been investigated in experimental models involving:

• Systemic lupus erythematosus (SLE)

• Sarcoidosis

• Inflammatory bowel disease

• Immune-mediated disorders

Scientists continue evaluating how tissue-protective signaling may influence autoimmune pathways.

Diabetes Research

Research has examined possible relationships between ARA-290 and:

• Neuropathy associated with diabetes

• Glucose regulation

• HbA1c changes

• Tissue repair in diabetic models

Additional research remains necessary to better understand these mechanisms.

Research Limitations

Although ARA-290 has progressed through multiple stages of clinical and preclinical investigation, many areas of research remain ongoing.

Results observed in laboratory, animal, and clinical studies should not be interpreted as proof of approved therapeutic applications outside approved research settings.

Further investigation is required to fully characterize its biological activity and safety profile.

Product Quality & Analytical Testing

Why Testing Matters

Research-grade ARA-290 should undergo testing to verify:

• Identity

• Purity

• Stability

• Potency

• Batch consistency

Common Testing Methods

High-Performance Liquid Chromatography (HPLC)

Used to evaluate peptide purity and detect impurities.

Mass Spectrometry (MS)

Used to verify peptide identity and molecular weight.

Identity Testing

Confirms peptide composition and sequence.

Stability Testing

Evaluates peptide integrity under storage conditions.

Batch Consistency Testing

Measures consistency across production lots.

Understanding ARA-290 Pricing

Several factors influence pricing between suppliers.

Product Purity

Higher purity preparations often command premium pricing.

Analytical Verification

Comprehensive testing programs improve transparency but increase production costs.

Manufacturing Standards

Strict quality-control procedures often contribute to higher pricing.

Peptide Complexity

Specialized peptides frequently require more advanced synthesis and verification.

Vendor Reputation

Trusted peptide manufacturers often charge more due to established quality-assurance programs.

ARA-290 Vendor Evaluation Checklist

Quality Verification

✅ Third-party testing available

✅ Certificate of Analysis provided

✅ Identity verification documented

✅ Purity information disclosed

✅ Batch-specific testing available

Vendor Reliability

✅ Positive customer reviews

✅ Transparent business information

✅ Responsive customer support

✅ Reliable inventory availability

Purchasing Experience

✅ Secure checkout process

✅ Shipment tracking available

✅ Clear refund policy

✅ Consistent order fulfillment

Red Flags When Comparing Vendors

Testing Concerns

❌ No third-party testing

❌ Missing COAs

❌ Unverified purity claims

❌ Outdated laboratory reports

Transparency Issues

❌ Hidden specifications

❌ Missing batch numbers

❌ Limited documentation

❌ No company contact information

Service Problems

❌ Frequent stock shortages

❌ Poor customer communication

❌ Negative customer reviews

❌ Unclear shipping policies

How to Choose the Best ARA-290 Vendor

Prioritize Testing Transparency

Choose suppliers providing independent testing and batch-specific Certificates of Analysis.

Compare Overall Value

Balance pricing against purity, testing quality, and customer support.

Review Product Documentation

Verify laboratory reports before purchasing.

Consider Supplier Reputation

Established vendors often provide stronger quality assurance and greater consistency.

Match Products to Research Objectives

Select products and suppliers that meet the analytical and documentation requirements of your laboratory.

Frequently Asked Questions

What is ARA-290?

ARA-290 (Cibinetide) is an erythropoietin-derived peptide studied for tissue-protective, anti-inflammatory, regenerative, and neuropathy-related research applications.

What is ARA-290 used for in research?

Researchers investigate ARA-290 in studies involving neuropathic pain, immune modulation, tissue repair, wound healing, inflammation, and vascular biology.

Why compare ARA-290 vendors?

Product purity, testing standards, documentation quality, supplier reputation, and pricing can vary significantly between vendors.

What should researchers review before purchasing?

Researchers should evaluate:

• Certificate of Analysis

• Purity testing

• Third-party verification

• Identity confirmation

• Vendor reputation

• Customer reviews

Why is third-party testing important?

Independent testing helps verify product identity, purity, and consistency while improving transparency.

Is the cheapest supplier always the best option?

No. Product quality, testing standards, transparency, and supplier reliability are often more important than price alone.

How often should vendor comparisons be updated?

Pricing, inventory, testing reports, and supplier policies can change frequently and should be reviewed regularly.

Final Thoughts

ARA-290 is one of the most promising tissue-protective peptides currently under investigation because of its unique ability to activate regenerative and anti-inflammatory pathways without reproducing the hematopoietic effects associated with erythropoietin. Researchers continue exploring its role in neuropathy, wound healing, immune modulation, vascular repair, inflammatory disease, and tissue-protection research.

When comparing ARA-290 vendors, researchers should prioritize purity verification, third-party testing, COA availability, supplier reputation, and overall value rather than focusing solely on price. A structured vendor comparison process can help identify suppliers that meet the highest research-quality standards.